Structure of the Abl protein kinase catalytic domain bound to a first-generation therapeutic, imatinib (PDB ID 1IEP; orange), which inspired medicinal chemists at Novartis to design an even more effective second-generation agent, nilotinib (PDB ID 3CS9; green). Both are U.S. FDA approved drugs used for treatment of chronic myeloid leukemiaRutgers, The State University of New Jersey
What do you want from the CBIIT website, social media, and email subscriptions? Your feedback will help us see how we are doing and ensure you get the information you want.